Masimo's smartSET™ FDA Clearance Offers Breakthrough Innovation in Pulse Oximetry to Help Improve Critical Patient Outcomes

RegulatoryapprovedsmartSETPositive

AI Analysis

Summary

Masimo announced FDA clearance of its smartSET pulse oximetry platform, which adds first-of-its-kind atrial fibrillation detection to previously cleared AI-enabled opioid-induced respiratory depression detection. The announcement is dated Oct. 17, 2026.

Outcome Details

FDA clearance for Masimo's smartSET pulse oximetry platform featuring AFib detection alongside previously cleared AI-enabled OIRD detection.

Importance:5/10

Sentiment:

0.60

FDA clearancemedical devicepulse oximetryatrial fibrillationAIOIRDMasimo

Related Companies

$TRAX

Read the original article

Published by PR Newswire Biotech on October 17, 2026 1:00 PM

Read Original